title: Tetanus toxoid coverage as an indicator of serological protection against neonatal tetanus.
abstract: OBJECTIVE
  A Multiple-Indicator Cluster Survey (MICS) was conducted at mid-decade in more than 60 developing countries to measure progress towards the year 2000 World Summit for Children goals. These goals included the protection of at least 90% of children against neonatal tetanus through the immunization of their mothers, as measured by tetanus toxoid (TT) coverage. In the Central African Republic (CAR), serological testing was added to the MICS to understand better the relationship between survey estimates of TT coverage and the prevalence of serological protection.
  
  
  METHODS
  In the CAR MICS, mothers of children younger than one year of age gave verbal histories of the TT vaccinations they had received, using the MICS TT questionnaire. A subsample of mothers was tested for tetanus antitoxin, using a double-antigen enzyme-linked immunoadsorbent assay (ELISA). Seropositivity was defined as a titre of > or =0.01 IU/ml, and TT coverage was defined as the proportion of mothers protected at delivery, according to their history of TT vaccinations.
  
  
  RESULTS
  Among the 222 mothers in the subsample, weighted TT coverage was 74.4% (95% Confidence Interval (CI); 67.0% - 81.7%) and tetanus antitoxin seroprevalence was 88.7% (95% CI; 83.2% - 94.2%). The weighted median antitoxin titre was 0.35 IU/ml.
  
  
  CONCLUSIONS
  Tetanus toxoid coverage in the CAR was lower than the prevalence of serological protection against neonatal tetanus. If this relationship holds for other countries, TT coverage estimates from the MICS may underestimate the extent to which the year 2000 goal for protecting children against neonatal tetanus was reached. We also showed that a high level of serological protection had been achieved in a country facing major public health challenges and resource constraints.
authors.affiliation: International Child Survival and Emerging Infections Program Support Activity, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30341-3724 USA. msd1@cdc.gov
authors.forename: Michael S
authors.initials: MS
authors.lastname: Deming
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Roungou
authors.forename: Max
authors.initials: M
authors.lastname: Kristiansen
authors.forename: Iver
authors.initials: I
authors.lastname: Heron
authors.forename: Alphonse
authors.initials: A
authors.lastname: Yango
authors.forename: Alexis
authors.initials: A
authors.lastname: Guenengafo
authors.forename: Robert
authors.initials: R
authors.lastname: Ndamobissi
mesh_terms: D002488:Central African Republic; D003906:Developing Countries; D005191:Family Characteristics; D005260:Female; D019538:Health Care Surveys; D006292:Health Priorities; D006801:Humans; D017589:Immunization Programs / Q000706:statistics & numerical data*; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000517:prevention & control*; D016015:Logistic Models; D011247:Pregnancy; D011795:Surveys and Questionnaires; D013742:Tetanus / Q000517:prevention & control*; D013745:Tetanus Toxoid / Q000008:administration & dosage*; D014944:World Health Organization
chemical_list: D013745:Tetanus Toxoid